p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.
暂无分享,去创建一个
[1] A. Tannapfel,et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines , 2002, International journal of cancer.
[2] G. Gores,et al. The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis* , 2001, The Journal of Biological Chemistry.
[3] C. Sherr. Parsing Ink4a/Arf “Pure” p16-Null Mice , 2001, Cell.
[4] D. Carrasco,et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.
[5] A. Berns,et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.
[6] G. Gores,et al. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. , 2001, Cancer research.
[7] G. Gores,et al. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[8] P. Pollock,et al. Mutation analysis of the CDKN2A promoter in Australian melanoma families , 2001, Nature Genetics.
[9] L. Liotta,et al. Laser Capture Microdissection , 2001, Current protocols in cell biology.
[10] A. Tannapfel,et al. Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver , 2000, Gut.
[11] Hoguen Kim,et al. p16 is a major inactivation target in hepatocellular carcinoma , 2000, Cancer.
[12] G. Gores,et al. The Bile Acid Taurochenodeoxycholate Activates a Phosphatidylinositol 3-Kinase-dependent Survival Signaling Cascade* , 2000, The Journal of Biological Chemistry.
[13] M. Serrano,et al. The INK4a/ARF locus in murine tumorigenesis. , 2000, Carcinogenesis.
[14] A. Romieu,et al. Oxidative base damage to DNA: specificity of base excision repair enzymes. , 2000, Mutation research.
[15] G. Gores,et al. Biliary tract cancers. , 1999, The New England journal of medicine.
[16] H. Pitt,et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. , 1999, The Journal of surgical research.
[17] H. Asakura,et al. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma , 1999 .
[18] C. Sherr,et al. Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.
[19] L. Liotta,et al. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. , 1998, Trends in genetics : TIG.
[20] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[21] D. Sidransky,et al. Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Bergquist,et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case‐control study , 1998, Hepatology.
[23] A. El‐Naggar,et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. , 1997, The American journal of pathology.
[24] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[25] Robert F. Bonner,et al. Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.
[26] M. Miwa,et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors , 1996, International journal of cancer.
[27] C. Sherr. Cancer Cell Cycles , 1996, Science.
[28] S. Tannenbaum,et al. DNA damage by nitric oxide. , 1996, Chemical research in toxicology.
[29] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[30] T. Goodrow,et al. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. , 1996, Cancer research.
[31] R. Kratzke,et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.
[32] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[33] R. Beart,et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.
[34] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[35] Kathleen R. Cho,et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.
[36] C. Cordon-Cardo. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.
[37] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[38] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[39] S. Hanai,et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. , 1995, Cancer research.
[40] B. Malassagne,et al. Primary sclerosing cholangitis: liver transplantation or biliary surgery. , 1995, Surgery.
[41] D. Carson,et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.
[42] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[43] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[44] Charles J. Sherr,et al. Mammalian G1 cyclins , 1993, Cell.
[45] L. Loeb,et al. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. , 1992, The Journal of biological chemistry.
[46] R. Wiesner,et al. Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis , 1991, Seminars in liver disease.
[47] J. Essigmann,et al. Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. , 1990, Biochemistry.
[48] G. Gores,et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. , 2001, Gastroenterology.
[49] G. Gores,et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.
[50] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[51] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.